ALPN Alpine Immune Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALPN

Price (delayed)

$64.57

Market cap

$4.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$4.2B

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, ...

Highlights
The quick ratio has surged by 109% since the previous quarter and by 90% year-on-year
Alpine Immune Sciences's equity has soared by 103% from the previous quarter and by 83% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.alpineimmunesciences.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ALPN
Market
Shares outstanding
65.55M
Market cap
$4.23B
Enterprise value
$4.2B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.44
Price to sales (P/S)
54.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
71.31
Earnings
Revenue
$58.88M
EBIT
-$31.98M
EBITDA
-$31.41M
Free cash flow
-$79.5M
Per share
EPS
-$0.64
Free cash flow per share
-$1.59
Book value per share
$5.64
Revenue per share
$1.18
TBVPS
$7.6
Balance sheet
Total assets
$379.85M
Total liabilities
$51.91M
Debt
$9.91M
Equity
$327.94M
Working capital
$288.05M
Liquidity
Debt to equity
0.03
Current ratio
7.86
Quick ratio
7.8
Net debt/EBITDA
1.08
Margins
EBITDA margin
-53.3%
Gross margin
100%
Net margin
-54.7%
Operating margin
-75.2%
Efficiency
Return on assets
-11.3%
Return on equity
-15.5%
Return on invested capital
-14.8%
Return on capital employed
-9.5%
Return on sales
-54.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALPN stock price

How has the Alpine Immune Sciences stock price performed over time
Intraday
0.03%
1 week
0.17%
1 month
64.13%
1 year
801.82%
YTD
238.77%
QTD
62.89%

Financial performance

How have Alpine Immune Sciences's revenue and profit performed over time
Revenue
$58.88M
Gross profit
$58.88M
Operating income
-$44.25M
Net income
-$32.18M
Gross margin
100%
Net margin
-54.7%
The gross profit has soared by 96% YoY and by 91% from the previous quarter
The company's revenue has surged by 96% YoY and by 91% QoQ
The net margin has soared by 72% year-on-year and by 70% since the previous quarter
ALPN's operating margin has surged by 65% since the previous quarter and by 61% year-on-year

Growth

What is Alpine Immune Sciences's growth rate over time

Valuation

What is Alpine Immune Sciences stock price valuation
P/E
N/A
P/B
11.44
P/S
54.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
71.31
Alpine Immune Sciences's EPS has surged by 63% YoY and by 50% QoQ
Alpine Immune Sciences's equity has soared by 103% from the previous quarter and by 83% YoY
The company's revenue has surged by 96% YoY and by 91% QoQ
The stock's price to sales (P/S) is 82% more than its 5-year quarterly average of 30.1

Efficiency

How efficient is Alpine Immune Sciences business performance
Alpine Immune Sciences's return on sales has surged by 70% YoY and by 70% QoQ
The company's return on equity has surged by 61% YoY and by 54% QoQ
The ROIC has soared by 57% YoY and by 48% QoQ
ALPN's ROA is up by 50% year-on-year and by 48% since the previous quarter

Dividends

What is ALPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALPN.

Financial health

How did Alpine Immune Sciences financials performed over time
The quick ratio has surged by 109% since the previous quarter and by 90% year-on-year
ALPN's current ratio has soared by 106% QoQ and by 89% YoY
The debt is 97% smaller than the equity
Alpine Immune Sciences's equity has soared by 103% from the previous quarter and by 83% YoY
The debt to equity has dropped by 63% year-on-year and by 50% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.